See p. 89. The prophylaxis dilemma. Jul 1999-31 Aug 1999. Selected highlights from the 6th Conference on Retroviruses and Opportunistic Infections. See p. 51-52.
Opportunistic infections update.
See p. 19-20. Maintenance fomivirsen eye injections. Treatment recommended for persons with positive CMV blood antigen tests. FDA approves fomivirsen, famciclovir, and thalidomide. A rocky road for nucleotide analogs.